Research programme: Alzheimer's disease therapeutics - KalGene Pharmaceuticals/National Research Council of Canada

Drug Profile

Research programme: Alzheimer's disease therapeutics - KalGene Pharmaceuticals/National Research Council of Canada

Alternative Names: ABP-BBB; KAL-ABP; KAL-ABP-BBB

Latest Information Update: 06 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Research Council Canada
  • Developer KalGene Pharmaceuticals; National Research Council Canada
  • Class Antibodies
  • Mechanism of Action Amyloid beta-protein modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 20 Jul 2017 Final preclinical study results in Alzheimer's disease presented at the Alzheimer's Association International Conference (AAIC-2017)
  • 16 Jul 2017 Pharmacokinetics and pharmacodynamics data from preclinical studies in Alzheimer's disease presented at the Alzheimer's Association International Conference 2017 (AAIC-2017)
  • 14 Jul 2017 Interim preclinical study results in Alzheimer's disease released by KalGene Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top